The latest awards were given to 29 medical institutions, including unrestricted and challenge grants to departments of ophthalmology at 22 medical schools and 22 awards to individual scientists.
The recently-approved grant projects include: a clinical trial of cyclosporin as a treatment for severe atopic keratoconjunctivitis (a severe and chronic form of ocular allergy that causes blindness in 70% of those who suffer from it); the study of possible relationships between optic nerve size, eyeball shape and focus error and the development of amblyopia (lazy eye); and an attempt to create three-dimensional imaging of retinal cells in the living eye, which will help advance our understanding of the cellular origins of age-related macular degeneration.
Among RPB's vision scientists fighting eye diseases are nine active Jules and Doris Stein RPB Professors who receive $375,000 each over five years and up to $100,000 in a matching grant for laboratory construction. An additional $150,000 may be awarded during a two-year extension of the award.
RPB currently supports eye research at 54 medical institutions throughout the United States. Since it was founded in 1960, RPB has channeled more than $220 million into eye research. As a result, RPB has been identified with nearly every major breakthrough in vision research in that time, including the development of laser surgery now used to treat diabetic retinopathy, glaucoma, macular degeneration, myopia, retinal detachment and astigmatism*, the invention of IOLs, the creation of modern diagnostic tools, the continuing evolution of ocular tissue transplants and the ongoing development of potential interventions at the genetic and molecular levels. RPB grants also support epidemiological studies, which inform treatment strategies, such as the recently released Ocular Hypertension Treatment Study (African-American Results).